Manuel López-Figueroa, PhD, is a Vice President at Bay City Capital and has been with the firm since July 2001. He specializes in evaluating investment opportunities with an emphasis on CNS. In addition, Dr. López is the Scientific Liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience and genetics from Stanford University, University of Michigan, Cornell University and the Universities of California at Davis and Irvine. The consortium aims to discover the neurobiological and genetic determinants of mood disorders and schizophrenia with the goal to develop novel diagnostics and therapeutics. Dr. López is responsible for planning and directing all aspects of the consortium including strategy, R&D, legal (IP & contracts) and financial, to facilitate the commercialization of discoveries to fund additional research. Dr. López has over 15 years of experience in the field of Neuroscience, has won numerous awards during his academic research career, and has published extensively. He completed post-doctoral work at the University of Michigan and at the University of Copenhagen, Denmark. Dr. López received a PhD in Medicine and Surgery, and a MS in Molecular and Cell Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.